NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Novel Biomarker USP22 and Immunotherapy Resistance
TL;DR
Northwestern Medicine's discovery of the USP22 biomarker offers a competitive edge by identifying immunotherapy-resistant patients early, enabling targeted treatments for better outcomes.
The USP22 biomarker works by predicting cancer patients' resistance to immunotherapy, providing a measurable target for developing alternative treatments for non-responders.
This discovery makes the world better by transforming care for immunotherapy-resistant patients, offering hope and improved treatment options where current methods fall short.
Scientists found a biological marker called USP22 that predicts immunotherapy resistance in cancer patients, potentially revolutionizing treatment approaches for those with limited options.
Found this article helpful?
Share it with your network and spread the knowledge!
Scientists at Northwestern Medicine have discovered a biological marker called USP22 that predicts which cancer patients are more resistant to immunotherapy.
This discovery has the potential to transform care for cancer patients whose current treatment options remain limited, particularly those who don't respond to immunotherapy.
USP22 is a biological marker that predicts resistance to immunotherapy in cancer patients and also points to a potential treatment target for non-responders.
Scientists at Northwestern Medicine conducted this research, and the findings were published in The Journal of Clinical Investigation.
The discovery could help identify patients who won't respond to immunotherapy and provide a new treatment target (USP22) for those non-responders, potentially improving outcomes for patients with limited options.
TinyGems is a specialized communications platform focused on innovative small-cap and mid-cap companies, and it published this article as part of its content distribution services.
You can read more about the research through the links provided in the content, including the original Northwestern Medicine article and The Journal of Clinical Investigation publication.
TinyGems provides: (1) access to wire solutions via InvestorWire, (2) article and editorial syndication to 5,000+ outlets, (3) enhanced press release enhancement, (4) social media distribution via IBN, and (5) tailored corporate communications solutions.
You can contact TinyGems at Editor@TinyGems.com, visit their website at https://www.TinyGems.com, or call their office at 512.354.7000.
Readers should review the full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, available at: https://www.TinyGems.com/Disclaimer
Curated from InvestorBrandNetwork (IBN)
